Sustained Complete Response to Brigatinib in a Young ALK+ NSCLC Patient
Managing Resistance in ALK-Positive Lung Cancer - Case Applying Precision Oncology Approach
In this expert case presentation, Dr. Akhil Kapoor shares the journey of a young, non-smoking patient with ALK-positive non-small cell lung cancer who developed resistance to alectinib due to an ALK I1171N mutation.
Through repeat molecular testing, the treatment was precisely adapted to brigatinib—leading to a remarkable and durable complete response, including CNS disease control.
This case highlights the importance of repeat molecular testing for guiding treatment sequencing and demonstrates brigatinib's effectiveness against specific ALK resistance mutations, underscoring the role of precision oncology in personalized therapy for ALK-positive NSCLC.
Key takeaway: Not all ALK inhibitors are interchangeable; treatment must be mutation-specific. Individualised approach is important
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.